Evidence map›Paper›PMID 35173532›Full record

ArticleInternational journal of biological sciences2022

Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma.

Ding Peng, Anbang He, Shiming He, Guangzhe Ge, Shuo Wang, Weimin Ci, Xuesong Li, Dan Xia, Liqun Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  16. Article
  17. Review
  18. The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ding PengDepartment of Urology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, P.R. China.
Anbang HeDepartment of Urology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, P.R. China.
Shiming HeDepartment of Urology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, P.R. China.
Guangzhe GeKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, No.1 Beichen West Road, Beijing,100101, P.R. China.
Shuo WangDepartment of Urology, The First Affiliated Hospital School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang Province 310003, P.R. China.
Weimin CiKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, No.1 Beichen West Road, Beijing,100101, P.R. China.
Xuesong LiDepartment of Urology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, P.R. China.
Dan XiaDepartment of Urology, The First Affiliated Hospital School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang Province 310003, P.R. China.
Liqun ZhouDepartment of Urology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, P.R. China.
Peking University · CNFirst Affiliated Hospital Zhejiang University · CNBeijing Institute of Genomics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exploring the regulatory mechanism of PD-L1 in renal cancer is one of the key strategies to improve the response of renal cancer patients to checkpoint blockade therapy. In this study, the synergistic effect of ascorbic acid (vitamin C) supplementation and the impact of TET2 depletion on anti-PD-L1 therapy were determined in xenograft model experiments. Lymphocyte infiltration and chemokine expression were determined using flow cytometry and qRT-PCR. To determine the downstream targets of TET2, we performed hMeDip-seq and RNA-seq analyses. The molecular mechanism was further confirmed by hMeDip-qPCR, MeDip-qPCR, bisulfite sequencing, Western blotting, qRT-PCR and xenograft model experiments

Indexed as

Carcinoma, Renal CellDioxygenasesKidney NeoplasmsAscorbic AcidB7-H1 AntigenCell Line, TumorChemokinesCytokinesDNA-Binding ProteinsEnzyme ActivationFemaleHumansImmunotherapyMaleAscorbic AcidB7-H1 AntigenChemokinesCytokinesDioxygenasesDNA-Binding ProteinsTET2 protein, humanAscorbic acidDNA hydroxymethylationImmunotherapyRenal cell carcinomaTET2

Identifiers

PMID35173532
PMCPMC8771844
OpenAlexW4206513761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.